Lifestyle modifications and control of cardiometabolic risk factors are foundational to the management of all patients with metabolic dysfunction–associated steatotic liver disease, but those with steatohepatitis and moderate fibrosis who are at risk of developing advanced liver disease may also need more targeted pharmacologic therapy, according to hepatologist Zobair M. Younossi, MD, MPH.
Weight loss is a critical starting point, Dr. Younossi said. For patients who are overweight or